SG
ADAP

StoneX Group’s Adaptimmune Therapeutics ADAP Stock Holding History

StoneX Group’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,040
Closed -$1.96K – 1088
2025
Q3 		$1.96K Buy
+15,040
New +$2.06K ﹤0.01% 924
2023
Q1 		– Sell
-11,431
Closed -$16.7K – 443
2022
Q4 		$16.7K Buy
+11,431
New +$18.5K ﹤0.01% 434

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

StoneX Group's ADAP Position: Q4 2025 in Review

StoneX Group sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 15,040 shares — an estimated $1.96K sold.

StoneX Group first reported a position in ADAP in Q4 2022 and held it in 2 quarters. The position peaked at $16.7K in Q4 2022. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • StoneX Group reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • StoneX Group sold 15,040 Adaptimmune Therapeutics shares in Q4 2025, an estimated $1.96K.
  • StoneX Group first reported a position in Adaptimmune Therapeutics in Q4 2022 and held it in 2 quarters.
  • StoneX Group's Adaptimmune Therapeutics position peaked at $16.7K in Q4 2022.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on StoneX Group's 13F filing for Q4 2025, filed 12 Feb 2026.